Sunshine Biopharma has launched nine new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one. The Company’s marketing and sales efforts are carried out by Nora Pharma, a wholly owned subsidiary of the Company. The new generic prescription drugs launched include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanzema, Progesterone, Rivaroxaban, and Zoledronic Acid. These new drugs address various human health areas including oncology, anti-inflammatory, antibacterial, dermatology, endocrinology, cardiovascular, and osteoporosis. These nine drugs were included in the list of “Products on the Market” provided in our recently filed 10-Q/A for the quarter ended June 30, 2024. They are currently being sold under distribution agreements instead of Nora Pharma’s commonly used cross-licensing arrangements. The current marketing arrangement for these drugs may change in the future.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBFM: